Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension

A Y Litvin, Z N Sukmarova, E M Elfimova, A V Aksenova, P V Galitsin, A N Rogoza, I E Chazova, A Y Litvin, Z N Sukmarova, E M Elfimova, A V Aksenova, P V Galitsin, A N Rogoza, I E Chazova

Abstract

Background: The aim of this study was to assess the effects of continuous positive airway pressure (CPAP) on arterial stiffness, central blood pressure, and reflected pulse wave characteristics in patients with severe obstructive sleep apnea (OSA) and stage 2-3 arterial hypertension.

Methods: Forty-four patients with hypertension and severe OSA (apnea/hypopnea index > 30) received stepped dose titration of antihypertensive treatment, consisting of valsartan 160 mg + amlodipine 5-10 mg + hydrochlorothiazide 25 mg. CPAP therapy was added after 3 weeks of continuous antihypertensive treatment with BP < 140/90 mmHg or after adjusting triple treatment in patients with resistant arterial hypertension. The patients were randomized to effective CPAP (4-15 mm H2O) or placebo CPAP (pressure 4 mm H2O) for three weeks, then crossed over to the alternative treatment in a single-blind manner. Office blood pressure (BP), ambulatory BP monitoring, ambulatory arterial stiffness index (AASI), aortic BP, carotid-femoral pulse wave velocity (cfPWV), and systolic wave augmentation index were measured using a Sphygmocor® device at baseline, after antihypertensive treatment, placebo CPAP, and effective CPAP.

Results: Baseline cfPWV was above the normal range in 94% of patients. After reaching target BP, the cfPWV decreased by 1.9 ± 1.0 msec (P = 0.007). Effective CPAP achieved a further cfPWV reduction of 0.7 msec (P = 0.03). Increased arterial stiffness (pulse wave velocity > 12 msec) persisted in 35% of patients on antihypertensive treatment and effective CPAP, in 56% of patients on antihypertensive treatment alone, and in 53% of patients on placebo CPAP. Only the combination of antihypertensive treatment with effective CPAP achieved a significant reduction in augmentation index and AASI, along with a further reduction in aortic and brachial BP.

Conclusion: Effective CPAP for 3 weeks resulted in a significant additional decrease in office BP, ambulatory BP monitoring, central BP, and augmentation index, together with an improvement in arterial stiffness parameters, ie, cfPWV and AASI, in a group of hypertensive patients with OSA.

Trial registration: ClinicalTrials.gov NCT00801671.

Keywords: antihypertensive therapy; arterial stiffness; blood pressure; continuous positive airway pressure; hypertension; obstructive sleep apnea; ulse wave velocity.

Figures

Figure 1
Figure 1
Study design. Note: Of the remaining 44 patients, two subjects refused pCPAP because of complaints of “shortness of breath” and fail to fall asleep, This was taken into account in the statistical analysis. Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; val, valsartan; aml, amlodipine; HCT, hydrochlorothiazide; CPAP, continuous positive airways pressure; eCPAP, effective CPAP; pCPAP, placebo CPAP; OSA, obstructive sleep apnea.
Figure 2
Figure 2
Pulse wave velocity recordings (normal Note: *P < 0.05 vs AT. Abbreviations: AT, antihypertensive therapy; CPAP, continuous positive airways pressure; eCPAP, effective CPAP; pCPAP, placebo CPAP; PWV, pulse wave velocity.
Figure 3
Figure 3
Changes in carotid-femoral PWV and AASI after antihypertensive therapy and CPAP therapy. Notes: *P > 1.05 vs baseline; #P > 1.05 vs AHT. Abbreviations: AHT, antihypertensive therapy; eCPAP, effective continuous positive airways pressure; cfPWV, carotid-femoral pulse wave velocity; AASI, ambulatory arterial stiffness index.

References

    1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep- disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230–1235.
    1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008;52:686–717.
    1. McNicholas WT, Bonsignore MR. Management Committee of EU COST ACTION B26. Sleep apnea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29:156–178.
    1. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6:e1000132.
    1. Marin JM, Carrizo S, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046–1053.
    1. Pecker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7 year follow-up. Am J Respir Crit Care Med. 2002;166:159–165.
    1. Faccenda JF, Mackay TW, Boon NA, et al. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med. 2001;163:344–348.
    1. Pepperell JCT, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized parallel trial. Lancet. 2001;359:204–210.
    1. Ayers L, Ferry B, Craig S, Nicoll D, Stradling JR, Kohler M. Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea. Eur Respir J. 2009;33:574–580.
    1. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern Med. 2005;142:187–197.
    1. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest. 2001;119:1085–1091.
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
    1. Drager LF, Bortolotto LA, Figueiredo AC, Silva BC, Krieger EM, Lorenzi-Filho G. Obstructive sleep apnea, hypertension and their interaction on arterial stiffness and heart remodeling. Chest. 2007;13:1379–1386.
    1. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007;50:852–858.
    1. Vlachantoni IT, Dikaiakou E, Antonopoulos CN, Stefanadis C, Daskalopoulou SS, Petridou ET. Effects of continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea in arterial stiffness: a meta-analysis. Sleep Med Rev. 2013;17:19–28.
    1. Levy P, Pepin JL, Arnaud C, Baguet JP, Dematteis M, Mach F. Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis. 2009;51:400–410.
    1. Chung S, Yoon IY, Lee CH, Kim JW. The association of nocturnal hypoxemia with arterial stiffness and endothelial dysfunction in male patients with obstructive sleep apnea syndrome. Respiration. 2010;79:363–369.
    1. The Report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667–689. [No authors listed]
    1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2158.
    1. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2007;28:1462–1536.
    1. Van Bortel LM, Laurent S, Boutouyrie P, et al. Artery Society. European Society of Hypertension Working Group on Vascular Structure and Function. European Network for Noninvasive Investigation of Large Arteries Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–448.
    1. Rogoza AN, Kuznetsov AA. Central aortic blood pressure and augmentation index: comparison between Vasotens® and SphygmoCor® technology. Research Reports in Clinical Cardiology. 2012;3:27–33.
    1. Nagahama H, Soejima M, Uenomachi H, et al. Pulse wave velocity as an indicator of atherosclerosis in obstructive sleep apnea syndrome patients. Intern Med. 2004;43:184–188.
    1. Doonan RJ, Scheffler P, Lalli M, et al. Increased arterial stiffness in obstructive sleep apnea: a systematic review. Hypertens Res. 2011;34:23–32.
    1. Parati G, Lombardi C, Hedner J, et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30:633–646.
    1. Nichols WW, O’Rourke MF. McDonald’s Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 5th ed. London, UK: Hodder Arnold; 2005.
    1. Kohler M, Craig S, Nicoll D, et al. Endothelial function and arterial stiffness in minimally symptomatic obstructive sleep apnea. Am J Respir Crit Care Med. 2008;178:984–988.
    1. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the CAFE study. Circulation. 2006;113:1213–1225.
    1. Phillips CL, Yee B, Yang Q, et al. Effects of continuous positive airway pressure treatment and withdrawal in patients with obstructive sleep apnea on arterial stiffness and central BP. Chest. 2008;134:94–100.
    1. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897–1904.
    1. Shirai K, Utino J, Otsuka K, et al. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI) JAtherosclerosis Thromb. 2006 Apr;13(2):101–107.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren